

## **SLEEP APNEA CLINICAL TRIAL UPDATE**

**29<sup>th</sup> March 2016, Melbourne, Australia.**

Respiratory and nasal technology company Rhinomed Limited (ASX:RNO) today announced that its current Phase 1, Clinical Trial for its new INPEAP (Intra Nasal Positive Expiratory Air Pressure) technology for the treatment of Obstructive Sleep Apnea being conducted at Monash Health is nearing completion with 18 of the 20 patients having now completed the study.

The company expected the results of this independent trial to be finalised in early 2016, but now expects the final 2 patients to be recruited and for Monash Health to complete the study in the next six weeks.

The primary endpoints for the trial seek to confirm that moderate Obstructive Sleep Apnea can be attenuated through EPAP (Expiratory Positive Air Pressure) with the Rhinomed INPEAP device.

### **Media Enquiries**

Michael Johnson, CEO & Managing Director

+61 (03) 8416 0900

[mjohnson@rhinomed.global](mailto:mjohnson@rhinomed.global)

Follow us on **Twitter** @rhinomedceo and @theturbinecom

### **About Rhinomed Limited (ASX: RNO)**

Rhinomed Limited is a Melbourne, Australia based technology firm with a focus on nasal, respiratory and breathing management technologies. The company is developing and commercialising applications of its technology portfolio in the Sport, Sleep, Wellbeing and drug delivery markets. The company has two products in market (the Turbine for Sports and Exercise and Mute for Snoring and better Sleep) and is currently conducting a clinical trial of its new INPEAP technology targeting mild to moderate sleep apnoea. For more information, go to [www.Rhinomed.global](http://www.Rhinomed.global)